Skip to content


  • Meeting abstract
  • Open Access

Polimixin B use in treatment of multidrug-resistant Pseudomonas aeruginosa infection

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Critical Care20037 (Suppl 3) :P68

  • Published:


  • Intensive Care Unit
  • Urinary Tract
  • Tract Infection
  • Respiratory Tract
  • Urinary Tract Infection


To describe the use of polimixin B as treatment of multidrug-resistant (MDR) Pseudomonas aeruginosa infection.


In this retrospective study we describe the features and demographic data of 27 patients with MDR P. aeruginosa treated with polimixin B, admitted to a private hospital medical and surgical intensive care unit (ICU).


Twenty-three patients (85.2%) were infected with MDR P. aeruginosa, confirmed with cultures and resistance tests, during the ICU stay. In greater part, they were isolated from respiratory and urinary tract infections (33.3% and 25.9%, respectively). Four patients were treated empirically, with 50% of therapy response. The study group presented a mean age of 63 years, 51.9% males, with a mean Acute Physiology and Chronic Health Evaluation II score of 24.63. Sixty-three percent of our patients were first admitted to the hospital with community-acquired infection, none caused by P. aeruginosa. The most frequent cause for ICU admission was communitarian or nosocomial respiratory tract infection (29.9%). The mean time of polimixin B use was 15.59 days. Twelve patients (44%) used imipinem, 12 patients (44%) used teicoplanin and three patients (11%) used vancomicin, for more than 3 days, during the ICU stay before polimixin B use. After treatment with polimixin B, we had 40.7% response and improvement and 59.3% death.


After this series, we suggest that polimixin B can be a useful alternative for treatment of MDR P. aeruginosa infection.

Authors’ Affiliations

SSA, BA, Hospital Português Study and Research Center, Hospital Português, Salvador, Bahia, Brazil


  1. Sader HS, et al.: Epidemiologic typing of multiply drug-resistant Pseudomonas aeruginosa isolated from an outbreak in an intensive care unit. Diagn Microbiol Infect Dis 1993, 17: 13-18. 10.1016/0732-8893(93)90063-DView ArticlePubMedGoogle Scholar
  2. Bukholm G, et al.: An outbreak of multidrug-resistant Pseudomonas aeruginosa associated with increased risk of patient death in an intensive care unit. Infect Control Hosp Epidemiol 2002, 23: 441-446.View ArticlePubMedGoogle Scholar
  3. Bertrand X, et al.: Pseudomonas aeruginosa : antibiotic susceptibility and genotypic characterization of strains isolated in the intensive care unit. Clin Microbiol Infect 2001, 7: 706-708. 10.1046/j.1198-743x.2001.00345.xView ArticlePubMedGoogle Scholar


© BioMed Central Ltd 2003